Latest International Markets News

ImpediMed Limited has reported record quarterly revenue and cash receipts for Q2 FY25, alongside significant growth in reimbursement coverage and a robust sales pipeline, signaling strong momentum in its digital health platform business.

Orbital Corporation Ltd reports a strong quarterly update with 29 engines delivered, a debt-free balance sheet, and significant R&D grant funding supporting new engine development.

OncoSil Medical has secured new distribution agreements across key international markets and achieved critical regulatory milestones, while raising $8 million to fuel its growth in pancreatic cancer treatment.

Bio-Gene Technology Limited has advanced its bio-insecticide pipeline with two U.S. Department of Defense grants totaling A$3 million, alongside key regulatory and production milestones for Flavocide® and Qcide®.

Audeara Ltd reports a 70% jump in Q2 FY25 cash receipts, driven by new product launches and a major contract with Avedis Zildjian. The company’s expansion into Taiwan and international markets signals a promising growth trajectory.

Clever Culture Systems Ltd has achieved a key cashflow break-even milestone in Q4 2024, driven by strong sales growth from major pharmaceutical clients including AstraZeneca and Bristol Myers Squibb. The company is also advancing its product line with a new APAS® Contact Plate capability set for mid-2025 launch.

BauMart Holdings reports meaningful progress in expanding its distribution networks and strategic collaborations during the December 2024 quarter, positioning itself for growth across Indonesia, Australia, and the mining sector.

Jupiter Energy Limited reported steady oil sales revenue of approximately US$1.76 million for Q4 2024, driven entirely by domestic channels, alongside commissioning a key gas utilisation project and launching a $4 million capital raise.

Aroa Biosurgery has reported its first quarter of positive operating cash flow since listing on the ASX in 2020, alongside robust revenue growth projections and new regulatory approvals across key international markets.

Foresta Group Holdings has raised $3.1 million through a convertible note and share placement, while securing exclusive technology licensing and key offtake agreements to propel its flagship New Zealand biomass project.

TrivarX has secured positive feedback from the FDA on its pivotal trial design for MEB-001, an AI-driven algorithm targeting major depressive episode screening via sleep study data. The company is advancing site collaborations to launch a large-scale US trial.

Chemist Warehouse Group has delivered a standout first half in FY25, reporting record sales growth and a significant expansion in EBIT margins, driven by new store openings and international expansion.